Source: Benzinga
Although Thermo Fisher Scientific Inc. (NYSE: TMO ) seems well-positioned to generate robust organic revenue growth and healthy margin expansion going ahead, its stock valuation reflects the bright prospects, according to Credit Suisse. The Analyst Credit Suisse’s Erin Wright initiated coverage of Thermo Fisher Scientific with a Neutral rating and a price target of $341. The Thesis Thermo Fisher Scientific is “highly levered” to strong industry fundamentals and is poised to benefit from rising biopharma demand, Wright said in the note. She added that the company has increased its exposure to the faster-growing subsegments like biopharma, through organic investments as well as acquisitions. Within biopharma, Thermo Fisher Scientific is … Full story available on Benzinga.com
Leave a Reply